elp2kqi

Property	Value
?:abstract	BACKGROUND: After the 2002/2003 SARS outbreak, 30% of survivors exhibited persisting structural pulmonary abnormalities. The long-term pulmonary sequelae of coronavirus disease 2019 (COVID-19) are yet unknown, and comprehensive clinical follow-up data are lacking. METHODS: In this prospective, multicentre, observational study, we systematically evaluated the cardiopulmonary damage in subjects recovering from COVID-19 at 60 and 100 days after confirmed diagnosis. We conducted a detailed questionnaire, clinical examination, laboratory testing, lung function analysis, echocardiography, and thoracic low-dose computed tomography (CT). RESULTS: Data from 145 COVID-19 patients were evaluated, and 41% of all subjects exhibited persistent symptoms 100 days after COVID-19 onset, with dyspnea being most frequent (36%). Accordingly, patients still displayed an impaired lung function, with a reduced diffusing capacity in 21% of the cohort being the most prominent finding. Cardiac impairment, including a reduced left ventricular function or signs of pulmonary hypertension, was only present in a minority of subjects. CT scans unveiled persisting lung pathologies in 63% of patients, mainly consisting of bilateral ground-glass opacities and/or reticulation in the lower lung lobes, without radiological signs of pulmonary fibrosis. Sequential follow-up evaluations at 60 and 100 days after COVID-19 onset demonstrated a vast improvement of both, symptoms and CT abnormalities over time. CONCLUSION: A relevant percentage of post-COVID-19 patients presented with persisting symptoms and lung function impairment along with pulmonary abnormalities more than 100 days after the diagnosis of COVID-19. However, our results indicate a significant improvement in symptoms and cardiopulmonary status over time.
is ?:annotates of	<https://research.tib.eu/covid-19/entity/7elp2kqi_hasAnnotation_C0013404> <https://research.tib.eu/covid-19/entity/7elp2kqi_hasAnnotation_C0020542> <https://research.tib.eu/covid-19/entity/7elp2kqi_hasAnnotation_C0037088> <https://research.tib.eu/covid-19/entity/7elp2kqi_hasAnnotation_C0543419> <https://research.tib.eu/covid-19/entity/7elp2kqi_hasAnnotation_C1457887>
?:creator	<https://research.tib.eu/covid-19/entity/Sonnweber%2C_Thomas%3B_Sahanic%2C_Sabina%3B_Pizzini%2C_Alex%3B_Luger%2C_Anna%3B_Schwabl%2C_Christoph%3B_Sonnweber%2C_Bettina%3B_Kurz%2C_Katharina%3B_Koppelst%C3%A4tter%2C_Sabine%3B_Haschka%2C_David%3B_Petzer%2C_Verena%3B_Boehm%2C_Anna%3B_Aichner%2C_Magdalena%3B_Tymoszuk%2C_Piotr%3B_Lener%2C_Daniela%3B_Theurl%2C_Markus%3B_Lorsbach-K%C3%B6hler%2C_Almut%3B_Tancevski%2C_Amra%3B_Schapfl%2C_Anna%3B_Schaber%2C_Marc%3B_Hilbe%2C_Richard%3B_Nairz%2C_Manfred%3B_Puchner%2C_Bernhard%3B_H%C3%BCttenberger%2C_Doris%3B_Tschurtschenthaler%2C_Christoph%3B_A%C3%9Fhoff%2C_Malte%3B_Peer%2C_Andreas%3B_Hartig%2C_Frank%3B_Bellmann%2C_Romuald%3B_Joannidis%2C_Michael%3B_Gollmann-Tepek%C3%B6yl%C3%BC%2C_Can%3B_Holfeld%2C_Johannes%3B_Feuchtner%2C_Gudrun%3B_Egger%2C_Alexander%3B_Hoermann%2C_Gregor%3B_Schroll%2C_Andrea%3B_Fritsche%2C_Gernot%3B_Wildner%2C_Sophie%3B_Bellmann-Weiler%2C_Rosa%3B_Kirchmair%2C_Rudolf%3B_Helbok%2C_Raimund%3B_Prosch%2C_Helmut%3B_Rieder%2C_Dietmar%3B_Trajanoski%2C_Zlatko%3B_Kronenberg%2C_Florian%3B_W%C3%B6ll%2C_Ewald%3B_Weiss%2C_G%C3%BCnter%3B_Widmann%2C_Gerlig%3B_L%C3%B6ffler-Ragg%2C_Judith%3B_Tancevski%2C_Ivan>
?:doi	<https://research.tib.eu/covid-19/entity/10.1183/13993003.03481-2020>
?:doi	10.1183/13993003.03481-2020
?:journal	Eur_Respir_J
?:license	cc-by-nc
?:pdf_json_files	document_parses/pdf_json/33ffa8f8b65281dac2a070070e7ea3266eccbb94.json
?:pmc_json_files	document_parses/pmc_json/PMC7736754.xml.json
?:pmcid	<https://research.tib.eu/covid-19/entity/PMC7736754>
?:pmid	<https://research.tib.eu/covid-19/entity/33303539.0>
?:pmid	33303539.0
?:publication_isRelatedTo_Disease	<https://research.tib.eu/covid-19/entity/COVID-19>
?:sha_id	<https://research.tib.eu/covid-19/entity/33ffa8f8b65281dac2a070070e7ea3266eccbb94>
?:source	Medline; PMC
?:title	Cardiopulmonary recovery after COVID-19 – an observational prospective multi-center trial
?:type	<https://research.tib.eu/covid-19/vocab/Publication>
?:year	2020-12-10

Property

Value

?:abstract

BACKGROUND: After the 2002/2003 SARS outbreak, 30% of survivors exhibited persisting structural pulmonary abnormalities. The long-term pulmonary sequelae of coronavirus disease 2019 (COVID-19) are yet unknown, and comprehensive clinical follow-up data are lacking. METHODS: In this prospective, multicentre, observational study, we systematically evaluated the cardiopulmonary damage in subjects recovering from COVID-19 at 60 and 100 days after confirmed diagnosis. We conducted a detailed questionnaire, clinical examination, laboratory testing, lung function analysis, echocardiography, and thoracic low-dose computed tomography (CT). RESULTS: Data from 145 COVID-19 patients were evaluated, and 41% of all subjects exhibited persistent symptoms 100 days after COVID-19 onset, with dyspnea being most frequent (36%). Accordingly, patients still displayed an impaired lung function, with a reduced diffusing capacity in 21% of the cohort being the most prominent finding. Cardiac impairment, including a reduced left ventricular function or signs of pulmonary hypertension, was only present in a minority of subjects. CT scans unveiled persisting lung pathologies in 63% of patients, mainly consisting of bilateral ground-glass opacities and/or reticulation in the lower lung lobes, without radiological signs of pulmonary fibrosis. Sequential follow-up evaluations at 60 and 100 days after COVID-19 onset demonstrated a vast improvement of both, symptoms and CT abnormalities over time. CONCLUSION: A relevant percentage of post-COVID-19 patients presented with persisting symptoms and lung function impairment along with pulmonary abnormalities more than 100 days after the diagnosis of COVID-19. However, our results indicate a significant improvement in symptoms and cardiopulmonary status over time.

is ?:annotates of